Drug Approval | December 14, 2025
FDA completes inspection of SMS Pharma’s Vizag facility
The inspection concluded with one minor observation in Form 483
The inspection concluded with one minor observation in Form 483
The approval by the US FDA comes after extensive safety testing and manufacturing improvements
SMS Pharmaceuticals has reported total income of Rs. 243.86 crore during the period ended September 30, 2025
The inspection, conducted from June 23 to June 25, 2025, concluded with zero Form 483 observations
SMS Pharmaceuticals has reported total income of Rs. 196.64 crores during the period ended June 30, 2025
The inspection concluded with zero Form 483 observations
This significant milestone enhances our global regulatory standing
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
The inspection conducted by EDQM at its Visakhapatnam facility
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated
